Study S003322

A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate Efficacy, Safety, and Tolerability of HM15275 for 36 Weeks in Obese or Overweight Subjects Without Diabetes Mellitus

ClinicalTrials.gov record

Registration

Registration: NCT07205900
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: TRIPLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 267
Start: 2025-12-02
Primary completion: 2027-01
Lead sponsor: Hanmi Pharmaceutical Company Limited
Conditions: Obese; Obesity
Interventions: DRUG:HM15275; DRUG:Placebo of HM15275
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Percent Change in Body Weight. [Up to 41 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.